FlunisolideThird Party Manufacturing in India

Flunisolide works by diffusing across cell membranes to bind with high affinity to cytosolic glucocorticoid receptors. It binds to these receptors to help the body downregulate the transcription of inflammatory genes and suppress synthesis of cytokines, leukotrienes, and prostaglandins. Unlike systemic steroid molecules, its pronounced topical affinity ensures that the drug treats inflamed mucosal tissue directly before undergoing rapid first-pass hepatic metabolism. It is highly effective and well-tolerated for reducing long-term airway hyperresponsiveness.

Therapeutic Uses

• Allergic Rhinitis: Suppresses perennial and seasonal allergic upper respiratory symptoms including nasal pruritus, rhinorrhea, and severe sneezing.
• Nasal Polyposis: Reduces the structural size and prevents recurrence of inflammatory nasal polyps following surgical resection.
• Non-Allergic Rhinitis: Manages chronic vasomotor rhinitis non-responsive to conventional first-generation antihistamine treatments.

Why Manufacturers Choose Flunisolide

Flunisolide third party manufacturing in India is increasingly leveraged by procurement agents seeking to offer diversified corporate respiratory portfolios. The steady global demand for non-sedating, anti-inflammatory nasal therapies makes this premium steroid a highly lucrative asset for high-volume export markets. Celesta delivers premium contract options for this molecule, confirming that our partner facilities are WHO-GMP certified to manage micro-suspension filling and particle size optimization.